ArticleCancer gene therapy2025
Cell-intrinsic platinum response and associated genetic and gene expression signatures in ovarian cancer.
Article in Cancer gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- An organoid-guided platform for ovarian cancer: enabling prediction of patients' chemotherapy response.Journal of ovarian research · 2026Article
- Nitric oxide-dependent stabilization of vimentin confers chemoresistance in ovarian cancer.Molecular therapy. Nucleic acids · 2026Article
- Synergistic Effects of Doxorubicin and Quercetin on ROS-Associated Apoptosis and EGFR/FOXP3 Modulation in OVCAR3 Cells.Biomedicines · 2026Article
- Exosomal circVANGL1 promotes cisplatin resistance in osteosarcoma cells by regulating the miR-145-5p/E2F3 axis.Discover oncology · 2026Article
- Cell-intrinsic and tumor microenvironmental determinants of platinum resistance in epithelial ovarian cancer.Discover oncology · 2026Review
- Article
- Article
- Keratin 5 expression defines a niche-supported hierarchy in tubo-ovarian cancer.Cancer heterogeneity and plasticity · 2026Article
- Multimodal AI in high-grade serous ovarian cancer: integrated prediction and clinical decision-making.Frontiers in oncology · 2026Review
- Models of high-grade serous carcinoma of tubo-ovarian origin.Oncology reviews · 2026Review
- Combined inhibition of NAD synthesis and C-terminal binding protein cooperatively induces cell death and inhibits growth of high grade serous ovarian carcinoma.Scientific reports · 2025Article
- Article
- Gallic acid potentiates the anticancer efficacy of cisplatin in ovarian cancer cells through modulation of the PI3K/AKT/mTOR and CXCL12/CXCR4 signaling pathways.Frontiers in oncology · 2025Article
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
Ovarian cancers are still largely treated with platinum-based chemotherapy as the standard of care, yet few biomarkers of clinical response have had an impact on clinical decision making. Previous work has relied on poor models of the most common subtypes of epithelial ovarian cancers and necessitates a careful examination of the most suitable in vitro models. We performed extensive drug dose response assays and gene expression profiling on 36 ovarian cancer cell lines across over seven subtypes. This is the largest quantitative database of quantitative cisplatin and carboplatin response in ovarian cancer cell lines. Our results demonstrate that cell lines largely fall either well above or below the clinical maximally achievable dose (C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.